These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38907601)

  • 1. Nanoparticles-encapsulated doxorubicin alleviates drug resistance of osteosarcoma via inducing ferroptosis.
    Tian X; Zhang Y; Zhang M; Liu G; Hao Y; Liu W
    Nanotoxicology; 2024 Jun; 18(4):401-409. PubMed ID: 38907601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
    Qiu R; Sun D; Bai Y; Li J; Wang L
    Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ethylene glycol) shell-sheddable TAT-modified core cross-linked nano-micelles: TAT-enhanced cellular uptake and lysosomal pH-triggered doxorubicin release.
    Zhang Y; Xiao Y; Huang Y; He Y; Xu Y; Lu W; Yu J
    Colloids Surf B Biointerfaces; 2020 Apr; 188():110772. PubMed ID: 31999965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIAH1/ZEB1/IL-6 axis is involved in doxorubicin (Dox) resistance of osteosarcoma cells.
    Han X; Liu F; Zhang C; Ren Z; Li L; Wang G
    Biol Chem; 2019 Mar; 400(4):545-553. PubMed ID: 30265649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA-PVT1 Inhibits Ferroptosis through Activating STAT3/GPX4 Axis to Promote Osteosarcoma Progression.
    Li G; Feng J; Huang S; Li Q
    Front Biosci (Landmark Ed); 2024 May; 29(6):207. PubMed ID: 38940027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy between isobavachalcone and doxorubicin suppressed the progression of anaplastic thyroid cancer through ferroptosis activation.
    Lin S; Cai H; Song X
    Braz J Med Biol Res; 2024; 57():e13679. PubMed ID: 39166605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
    Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
    J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
    Li Y; Hou H; Zhang P; Zhang Z
    Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.
    Haghiralsadat F; Amoabediny G; Naderinezhad S; Zandieh-Doulabi B; Forouzanfar T; Helder MN
    Int J Nanomedicine; 2018; 13():3853-3866. PubMed ID: 30013340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of ABCG2 is associated with chemotherapy resistance of osteosarcoma.
    Shu H; Yuan B; Huang Y; Wang L; He B; Sun Q; Sun L
    J Orthop Surg Res; 2021 Jan; 16(1):85. PubMed ID: 33509236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Encapsulation of verapamil and doxorubicin by MPEG-PLA to reverse drug resistance in ovarian cancer.
    Zheng W; Li M; Lin Y; Zhan X
    Biomed Pharmacother; 2018 Dec; 108():565-573. PubMed ID: 30243090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.
    Wang L; Wang W; Rui Z; Zhou D
    Drug Deliv; 2016 Nov; 23(9):3200-3208. PubMed ID: 26987435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
    Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
    Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22.
    Zhu K; Yuan Y; Wen J; Chen D; Zhu W; Ouyang Z; Wang W
    Aging (Albany NY); 2020 Apr; 12(8):6644-6666. PubMed ID: 32302291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
    Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
    Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
    Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
    Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery.
    Tam YT; To KK; Chow AH
    Colloids Surf B Biointerfaces; 2016 Mar; 139():249-58. PubMed ID: 26724466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
    Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy.
    Shao Y; Luo W; Guo Q; Li X; Zhang Q; Li J
    Drug Des Devel Ther; 2019; 13():2043-2055. PubMed ID: 31388296
    [No Abstract]   [Full Text] [Related]  

  • 20. circ_0002060 Enhances Doxorubicin Resistance in Osteosarcoma by Regulating the miR-198/ABCB1 Axis.
    Ji Y; Liu J; Zhu W; Ji J
    Cancer Biother Radiopharm; 2023 Nov; 38(9):585-595. PubMed ID: 33351694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.